Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Size To Grow At 14.1% CAGR From 2025 to 2030

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Size ( 2025 - 2030 )

As per our research report, the global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market size is estimated to grow at a CAGR of 14.1% from 2025 to 2030. 

An increasingly common option for treating opioid use disorder (OUD) is naltrexone. It helps avoid relapse by blocking opioid receptors and is non-addictive. The monthly injectable version, Vivitrol, makes it easier for patients since they don’t have to take it daily. With more awareness and insurance coverage increasing, more people, especially in outpatient settings, are choosing it. Naltrexone is also part of longer-term treatment plans that focus on recovery and keeping people from relapsing.
On the other hand, buprenorphine still leads in the OUD treatment market, holding a big share of global sales. It works as a partial opioid agonist, easing withdrawal symptoms and cravings while reducing misuse and overdose risks. Options like sublingual tablets, films, and the injectable Sublocade give patients flexibility in treatment.

Market expansion is driven by technological advancements in treatment options. Expansion of digital assistance and telemedicine. By enabling online counseling and remote appointments, telehealth has revolutionized the way we treat opioid use problems. People in remote areas, who might not have easy access to care, will particularly benefit from this. It makes asking for assistance less daunting and more convenient.

Through improved insurance coverage, new government initiatives are facilitating access to medication-assisted treatment. Access to these treatments is made easier by regulatory changes, such as the removal of the requirement for prior authorization for prescriptions of buprenorphine. This motivates more medical professionals to give their patients a range of choices.

The market for buprenorphine treatment of opioid use disorder is expanding due to advancements in technology, improved medical practices, and beneficial legislative reforms. Through online consultations and therapy, telemedicine, and digital therapies are helping people, particularly those living in rural places, get the assistance they require. Drugs like Brixadi and Sublocade are becoming more and more popular since they require fewer doses, which makes it simpler for patients to adhere to their medication. Additionally, by integrating digital health tools, physicians can make real-time treatment adjustments, which improves outcomes. More healthcare professionals are able to give care thanks to recent legislative changes that are removing outdated restrictions, such as loosening prescription regulations and increasing insurance coverage for medication-assisted treatment.

By increasing the use of telemedicine services, the COVID-19 pandemic altered the way that buprenorphine is used to treat opioid use disorder. Prescriptions for buprenorphine had to be obtained in person before the pandemic, but new regulations made it possible for doctors to begin and oversee treatment remotely, even over the phone. This made it simpler for people who live in remote places and don't have easy access to medical care to receive assistance. According to research, telemedicine decreased the danger of overdosing and assisted patients in continuing to take their medications during the pandemic. Veterans Health Administration data, for example, showed that the majority of buprenorphine visits shifted to telehealth, with many individuals choosing phone conversations over video chats due to convenience.

KEY MARKET INSIGHTS:  

• Based on market segmentation by Drug Class, an increasingly common option for treating opioid use disorder (OUD) is naltrexone. It helps avoid relapse by blocking opioid receptors and is non-addictive. Patients find it easier because they don't have to take the monthly injectable version, Vivitrol, every day. More people are selecting it, particularly in outpatient settings, as awareness and insurance coverage grow. Longer-term treatment programs that emphasize recovery and preventing relapses also include naltrexone. However, buprenorphine continues to dominate the OUD therapy industry, accounting for a significant portion of worldwide sales. As a partial opioid agonist, it lessens cravings and withdrawal symptoms while lowering the danger of abuse and overdose. Patients have more therapy options because of products like injectable Sublocade, films, and sublingual pills.
• Based on market segmentation by Route of Administration, in the market for treating opioid use disorders, the injectable form of buprenorphine, particularly long-acting versions like Sublocade and Brixadi, is expanding at the quickest rate. Patients find it simpler to adhere to their therapy when these weekly or monthly injections are administered since they help maintain consistent medication levels without the need for daily doses. More physicians and patients are using them to treat opioid use disorders since they also reduce the likelihood of abuse. However, the most popular route to take buprenorphine is orally. Suboxone and other sublingual tablets and films are well-liked due to their ease of administration, affordability, and demonstrated efficacy. Many people can get them because they are available at local pharmacies and provide variable dosing options.
• Based on market segmentation by Distribution Channel, in the market for buprenorphine treatment for opioid use disorder (OUD), online pharmacies are expanding rapidly. The use of telemedicine and digital health platforms is increasing, which makes it simpler to obtain OUD medicines. People in remote areas will particularly benefit from this, as it allows them to have their medicines delivered to their homes, ensuring they adhere to their treatment regimen. When online pharmacies collaborate with telehealth services, it facilitates continuous medication monitoring and accelerates their expansion. Hospital pharmacies already control a sizable portion of the buprenorphine market. They are essential in supplying OUD drugs, particularly to hospitalized patients or those requiring injections. Hospitals are able to administer drugs in a secure setting, guaranteeing that patients adhere to their prescribed regimen.
• Based on market segmentation by Treatment Approach, TeleMAT is rapidly expanding and combines medication-assisted treatment for opioid use disorder with telemedicine. It reaches those who might not have other options by providing remote access to buprenorphine medications and therapy through digital channels. This approach has gained popularity because it addresses practical and geographic issues while offering an adaptable way to address the opioid crisis. TeleMAT is becoming a more popular option for OUD management since it increases patient involvement and maintains them in treatment by combining medicine with online counseling. The primary treatment for opioid use disorders is buprenorphine, particularly when combined with naloxone (as in Suboxone). It is frequently used in a variety of therapeutic contexts and is successful in lowering cravings and withdrawal symptoms.
• Based on market segmentation by Emerging Trends, the rise of digital tools and telemedicine is the biggest trend in treating opioid use disorder with buprenorphine. The shift to remote care was accelerated by the COVID-19 pandemic, which had a long-lasting effect on treatment delivery. Studies indicate that initiating buprenorphine treatment via telemedicine improves retention. For example, in Kentucky, 48% of patients who started via telehealth stayed for 90 days, compared to 44% in regular settings. Only 28% of Ohioans continued receiving traditional care, compared to 32% who continued receiving telemedicine treatment.
  Changes in regulations are also a key trend in buprenorphine treatment. The 2022 MAT Act removed the DATA-2000 waiver for prescribers, making it easier for healthcare providers to prescribe buprenorphine.
• Based on market segmentation by Region, due to variations in healthcare systems, governmental regulations, and the prevalence of opioid use in various regions, the market for buprenorphine-based therapy for opioid use disorder is somewhat uneven worldwide. Thanks to robust medication-assisted treatment programs and strong regulatory backing in the United States, North America leads the pack with roughly 66% of the market. With about 20%, Europe follows, with nations including the UK, Germany, and France actively utilizing a range of therapeutic approaches. Although it only makes up 5% of the world's population, the Asia-Pacific area is expanding quickly due to increased opioid use and improved access to healthcare, particularly in China and India. Latin America is at roughly 4%, with more awareness and government efforts to tackle opioid addiction.
• Companies playing a leading role in the Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market profiled in this report are Indivior PLC, Alkermes PLC, Orexo AB, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., BioDelivery Sciences International, Inc., Camurus AB, Viatris Inc. (formerly Mylan N.V.), Braeburn Inc.

By  Drug Class

• Buprenorphine
• Methadone
• Naltrexone

By Route of Administration

• Injectable (Parenteral)
• Oral
• Transdermal and Nasal Spray

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

By Treatment Approach

• Pharmacotherapy
• Behavioral Therapy
• Supportive Services

By Emerging Trends

• Digital Therapeutics and Telemedicine
• Regulatory Changes

By Region 

• North America
• Asia-Pacific
• Europe
• South America
• Middle East and Africa

Request sample of this report @ https://virtuemarketresearch.com/report/buprenorphine-based-opioid-use-disorders-treatment-market/request-sample